Antinuclear Antibodies in Rheumatic Disease: A Proposal for a Function-Based Classification

Scandinavian Journal of Immunology

Volumn 76, Issue 3, 2012, Pages 223-228

  Pisetsky, D S ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; RNA BINDING PROTEIN;

CLINICAL FEATURE; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNITY; INFLAMMATION; NEPHRITIS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES;

EID: 84865398690     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02728.x     Document Type: Review

References (40)

1. Wandstrat AE, Carr-Johnson F, Branch V et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006;27:153-60.
2. Li QZ, Karp DR, Quan J et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011;13:R38.
3. Satoh M, Chan EK, Ho LA et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;Doi: 10.1002/art.34380. [Epub ahead of print].
4. Pisetsky DS. Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg? Arthritis Res Ther 2011;13:109.
5. Kaveri SV, Silverman GJ, Bayry J. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol 2012;188:939-45.
6. Notley CA, Brown MA, Wright GP, Ehrenstein MR. Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol 2011;186:4967-72.
7. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011;365:1612-23.
8. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
9. Bonfa E, Llovet R, Scheinberg M, De Souza JM. Comparison between autoantibodies in malaria and leprosy with lupus. Clin Exp Immunol 1987;70:529-37.
10. Adebajo AO, Charles P, Maini RN, Hazleman BL. Autoantibodies in malaria, tuberculosis and hepatitis B in a West African population. Clin Exp Immunol 1993;92:73-6.
11. Harley JB, James JA. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis 2006;64:45-51.
12. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
13. Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther 2008;10:218.
14. McCarty GA, Rice JR, Bembe ML, Pisetsky DS. Independent expression of autoantibodies in systemic lupus erythematosus. J Rheumatol 1982;9:691-5.
15. Hiepe F, Dömer T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170-8.
16. Pisetsky DS, Grammer AC, Ning TC, Lipsky PE. Are autoantibodies the targets of B-cell-directed therapy? Nat Rev Rheumatol 2011;7:551-6.
17. Kalaaji M, Fenton KA, Mortensen ES et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007;71:664-72.
18. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009;20:696-704.
19. Kruse K, Janko C, Urbonaviciute V et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010;15:1098-113.
20. Seredkina N, Rekvig OP. Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis. Am J Pathol 2011;179:1120-8.
21. Krishnan MR, Wang C, Marion TN. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int 2012;Doi: 10.1038/ki.2011.484. [Epub ahead of print].
22. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996;39:894-903.
23. Pisetsky DS, Ullal AJ. The blood nucleome in the pathogenesis of SLE. Autoimmun Rev 2010;10:35-7.
24. Beyer C, Stearns NA, Giessl A, Distler JH, Schett G, Pisetsky D. The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death. Innate Immun 2012; Doi: 10.1177/1753425912437981. [Epub ahead of print].
25. DeGiorgio LA, Konstantinov KN, Lee SC, hardin JA, Voipe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;11:1189-93.
26. Faust TW, Chang EH, Kowal C et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci USA 2010;1074:18569-74.
27. Vallin H, Perers A, Alm GV, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimc the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999;163:6306-13.
28. Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004;199:1631-40.
29. Tian J, Avalos AM, Mao S-Y et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
30. Wähämaa H, Schierbeck H, Hreggvidsdottir HS et al. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther 2001;13:R136.
31. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012;8:195-202.
32. Yang H, Lundbäck P, Ottosson L et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012;18:250-9.
33. Skinner RP, Maddison PJ. Analysis of polyethylene glycol precipitates from SLE era: antibody enrichment in association with disease activity. Clin Exp Rheumatol 1990;8:553-60.
34. Ahlin E, Mathsson L, Eloranta ML et al. Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus 2012;21:586-95.
35. Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1990;33:1378-83.
36. Abdulahad DA, Westra J, Blizet J et al. High mobility group box 1 (HMGB1) and anti-HMGB1antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011;13:R71.
37. Yang H, Ochani M, Li J et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301.
38. Schierbeck H, Lundbäck P, Palmblad K et al. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011;17:1039-44.
39. Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Marechal V. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med 2011;37:957-62.
40. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol 2011;187:2626-31.